The Lipid Core Group focuses its research interest on clinical trials. These studies include a placebo-controlled trial evaluating the efficacy of oat and plant sterols-containing cereals to lower total and LDL cholesterol. In addition, clinical trials involving the new superstatins, including rosuvastatin, are underway. Furthermore, safety and efficacy of an apolipoprotein A analog, which would selectively raise the HDL cholesterol level, is being tested in human trials. We are also currently participating in a multicenter trial of the effect of Ezetimibe on homozygous sitosterolemia. Newer weight-reducing drugs are also being evaluated as part of multicenter trials. With the addition of new core members, we plan to expand our research interests into kinetic studies of lipid metabolism. Additionally, physiology-based studies on the effect of lipid-lowering by drugs and/or by LDL apheresis are either under way or being contrived to determine their effects of vascular endothelial function and nitric oxide production.